IL273924B2 - Muscarinic acetylcholine M4 receptor antagonists - Google Patents
Muscarinic acetylcholine M4 receptor antagonistsInfo
- Publication number
- IL273924B2 IL273924B2 IL273924A IL27392420A IL273924B2 IL 273924 B2 IL273924 B2 IL 273924B2 IL 273924 A IL273924 A IL 273924A IL 27392420 A IL27392420 A IL 27392420A IL 273924 B2 IL273924 B2 IL 273924B2
- Authority
- IL
- Israel
- Prior art keywords
- cyclopenta
- hexahydro
- pyridazin
- phenyl
- pyrrol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574912P | 2017-10-20 | 2017-10-20 | |
| PCT/US2018/056803 WO2019079783A1 (en) | 2017-10-20 | 2018-10-20 | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273924A IL273924A (en) | 2020-05-31 |
| IL273924B1 IL273924B1 (en) | 2024-03-01 |
| IL273924B2 true IL273924B2 (en) | 2024-07-01 |
Family
ID=66173904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273924A IL273924B2 (en) | 2017-10-20 | 2018-10-20 | Muscarinic acetylcholine M4 receptor antagonists |
| IL310346A IL310346A (en) | 2017-10-20 | 2018-10-20 | Muscarinic acetylcholine M4 receptor antagonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310346A IL310346A (en) | 2017-10-20 | 2018-10-20 | Muscarinic acetylcholine M4 receptor antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11299481B2 (enExample) |
| EP (1) | EP3697759A4 (enExample) |
| JP (1) | JP7270989B2 (enExample) |
| KR (2) | KR102776114B1 (enExample) |
| CN (2) | CN111491920B (enExample) |
| AU (2) | AU2018351651B2 (enExample) |
| CA (1) | CA3079617A1 (enExample) |
| IL (2) | IL273924B2 (enExample) |
| WO (1) | WO2019079783A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311848B (zh) | 2016-06-07 | 2022-02-01 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| SMT202400385T1 (it) | 2017-03-23 | 2024-11-15 | Jacobio Pharmaceuticals Co Ltd | Nuovi derivati eterociclici utili come inibitori di shp2 |
| CN111108105B (zh) | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的杂环化合物 |
| KR102782563B1 (ko) | 2017-10-18 | 2025-03-14 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 이미다조-피리딘 화합물 |
| CN111491920B (zh) * | 2017-10-20 | 2024-01-30 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| US11352344B2 (en) | 2017-10-31 | 2022-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| HUE067265T2 (hu) | 2017-11-24 | 2024-10-28 | Jubilant Episcribe Llc | Heterociklusos vegyületek mint PRMT5 inhibitorok |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| CA3090130A1 (en) * | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3155864A1 (en) | 2019-10-04 | 2021-04-08 | Vanderbilt University | MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS |
| AU2020401560A1 (en) * | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US20230150986A1 (en) * | 2019-12-10 | 2023-05-18 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021174176A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| WO2021216951A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| JP2023522959A (ja) * | 2020-04-24 | 2023-06-01 | ヴァンダービルト ユニヴァーシティ | ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール |
| EP4196473B1 (en) * | 2020-08-13 | 2024-10-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20240010640A1 (en) * | 2020-11-18 | 2024-01-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| EP4267569B1 (en) * | 2020-12-22 | 2024-10-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) * | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| JP7525058B2 (ja) * | 2021-04-01 | 2024-07-30 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニスト |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| CN118076581A (zh) * | 2021-08-09 | 2024-05-24 | 维泰瑞隆有限公司 | 铁死亡调节剂、其制备和用途 |
| US20250101041A1 (en) * | 2022-01-19 | 2025-03-27 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138431A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726172A (en) * | 1996-01-16 | 1998-03-10 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| EP1521747B1 (en) * | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| DE60225195T2 (de) | 2002-12-23 | 2009-02-26 | Ranbaxy Laboratories, Ltd. | Flavaxat-derivate als muscarin-rezeptor antagonisten |
| US7517905B2 (en) | 2003-04-09 | 2009-04-14 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| ES2436888T3 (es) * | 2003-09-26 | 2014-01-07 | Exelixis, Inc | Moduladores c-Met y métodos de uso |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| EP1796667A2 (en) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP1904495A2 (en) | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| CN101230058A (zh) * | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| CN102686581B (zh) * | 2009-12-21 | 2015-08-26 | 张强 | 喹唑啉衍生物 |
| JP2012107001A (ja) | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| CN103102352B (zh) * | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| CN105189481A (zh) | 2013-03-13 | 2015-12-23 | 艾伯维公司 | 吡啶cdk9激酶抑制剂 |
| WO2015119899A1 (en) * | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN106458912B (zh) | 2014-04-04 | 2020-10-27 | 辉瑞公司 | 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途 |
| US9346815B2 (en) | 2014-05-23 | 2016-05-24 | Genentech, Inc. | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| HK1253029A1 (zh) | 2015-11-06 | 2019-06-06 | Neurocrine Biosciences, Inc. | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 |
| EP3416639B1 (en) * | 2016-02-16 | 2022-06-08 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3541373B1 (en) * | 2016-11-17 | 2023-11-01 | Merck Sharp & Dohme LLC | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| JP2020530451A (ja) | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| JP2020537667A (ja) | 2017-10-17 | 2020-12-24 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| CN111491920B (zh) | 2017-10-20 | 2024-01-30 | 范德比尔特大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| US11352344B2 (en) * | 2017-10-31 | 2022-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2020401560A1 (en) * | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US20230150986A1 (en) * | 2019-12-10 | 2023-05-18 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP2023522959A (ja) * | 2020-04-24 | 2023-06-01 | ヴァンダービルト ユニヴァーシティ | ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール |
| WO2021216951A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| EP4267569B1 (en) * | 2020-12-22 | 2024-10-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| US20240287050A1 (en) * | 2021-06-11 | 2024-08-29 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2018
- 2018-10-20 CN CN201880081828.0A patent/CN111491920B/zh active Active
- 2018-10-20 IL IL273924A patent/IL273924B2/en unknown
- 2018-10-20 JP JP2020521971A patent/JP7270989B2/ja active Active
- 2018-10-20 AU AU2018351651A patent/AU2018351651B2/en active Active
- 2018-10-20 CN CN202410064006.9A patent/CN118063442A/zh active Pending
- 2018-10-20 WO PCT/US2018/056803 patent/WO2019079783A1/en not_active Ceased
- 2018-10-20 CA CA3079617A patent/CA3079617A1/en active Pending
- 2018-10-20 IL IL310346A patent/IL310346A/en unknown
- 2018-10-20 KR KR1020207013966A patent/KR102776114B1/ko active Active
- 2018-10-20 KR KR1020257006587A patent/KR20250037575A/ko active Pending
- 2018-10-20 US US16/757,245 patent/US11299481B2/en active Active
- 2018-10-20 EP EP18869444.2A patent/EP3697759A4/en active Pending
-
2022
- 2022-03-07 US US17/688,709 patent/US11820757B2/en active Active
-
2023
- 2023-04-04 AU AU2023202086A patent/AU2023202086B2/en active Active
- 2023-10-13 US US18/486,712 patent/US20240116902A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007138431A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023202086A1 (en) | 2023-05-04 |
| CA3079617A1 (en) | 2019-04-25 |
| JP2021500345A (ja) | 2021-01-07 |
| US20210188820A1 (en) | 2021-06-24 |
| EP3697759A4 (en) | 2021-05-12 |
| JP7270989B2 (ja) | 2023-05-11 |
| AU2018351651B2 (en) | 2023-01-05 |
| US11299481B2 (en) | 2022-04-12 |
| CN111491920A (zh) | 2020-08-04 |
| KR20250037575A (ko) | 2025-03-17 |
| WO2019079783A1 (en) | 2019-04-25 |
| AU2018351651A1 (en) | 2020-06-04 |
| US11820757B2 (en) | 2023-11-21 |
| IL310346A (en) | 2024-03-01 |
| AU2023202086B2 (en) | 2025-04-03 |
| CN118063442A (zh) | 2024-05-24 |
| US20240116902A1 (en) | 2024-04-11 |
| KR102776114B1 (ko) | 2025-03-07 |
| US20220213069A1 (en) | 2022-07-07 |
| IL273924B1 (en) | 2024-03-01 |
| EP3697759A1 (en) | 2020-08-26 |
| KR20200074164A (ko) | 2020-06-24 |
| IL273924A (en) | 2020-05-31 |
| CN111491920B (zh) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273924B2 (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| JP2021500345A5 (enExample) | ||
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| CN106068262B (zh) | 喹唑啉衍生物及其制备方法和在医药上的应用 | |
| JP2010510319A5 (enExample) | ||
| HRP20212000T1 (hr) | Aminotriazolopiridini kao inhibitori kinaze | |
| HRP20190763T1 (hr) | Spojevi pirazina za liječenje zaraznih bolesti | |
| JP2017530185A5 (enExample) | ||
| HRP20191261T1 (hr) | Novi derivati pirazolo pirimidina i njihova uporaba kao inhibitora malt1 | |
| FI3514151T3 (fi) | Proteiinikinaasi c:n estäjiä ja niiden käyttötapoja | |
| JP2017523215A5 (enExample) | ||
| CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| RU2015135891A (ru) | Новые производные пиразола | |
| JP2019504009A5 (enExample) | ||
| IL276031B2 (en) | oxazine monoacylglycerol lipase (magl) inhibitors | |
| JP2012501312A5 (enExample) | ||
| JP2017524007A5 (enExample) | ||
| JP2014062093A5 (enExample) | ||
| RU2016124178A (ru) | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет | |
| HRP20180384T1 (hr) | Derivati 2,3-dihidro-benzo[1,4]oksazina i odgovarajući spojevi kao inhibitori kinaze fosfoinozitida-3 (pi3k) za liječenje primjerice reumatoidnog artritisa | |
| ME02856B (me) | Aminopirimidinilni spojevi kao inhibitori jak | |
| JP2018534326A5 (enExample) | ||
| RU2016137674A (ru) | Производные пиперидиндиона | |
| RU2018133391A (ru) | 1,5-дигидро-4н-пиразоло[3,4-d]пиримидин-4-оны и 1,5-дигидро-4н-пиразоло[4,3-c]пиридин-4-оны в качестве ингибиторов pde1 | |
| HRP20170119T1 (hr) | Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije |